The Conversation (0)
BioVie reported its financial report for the fiscal year 2017 and provided shareholders with a clinical development progress.
BioVie (OTCQB:BIVI) reported its financial report for the fiscal year 2017 and provided shareholders with a clinical development progress.
As quoted in the press release:
“BioVie has achieved key milestones and significantly advanced the business plan,” said CEO Jonathan Adams. “We will continue taking important steps toward BIV201 approval and commercialization and building company value for our shareholders.” BioVie is an emerging leader in the development of drug therapies for ascites and other life-threatening complications of advanced liver cirrhosis. The market potential for a therapy that can address these serious unmet medical needs is substantial, potentially exceeding $1 billion.
The Company has received FDA clearance to begin a mid-stage (Phase 2a) clinical trial in the US administering BIV201 to patients with refractory ascites, and dosing of the first patient is very close. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis, but is not available in the US or Japan.
Click here to read the full press release.
Source: www.marketwired.com
